Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02165397 · ClinicalTrials.gov registry record · Phase 3
Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia
A Phase 3 study, sponsored by Pharmacyclics.
- Completed
- Registry status
- Phase 3
- Development phase
- 181
- Enrollment target
NCT02165397 is a Phase 3 study that has completed, run by Pharmacyclics. The registered enrollment target is 181 participants.
The verdict
NCT02165397, a Phase 3 study, has completed, sponsored by Pharmacyclics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 181 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of ibrutinib in combination with rituximab in participants with Waldenström's macroglobulinemia (WM).
Interventions
- DRUG Placebo
- DRUG Rituximab
- DRUG Ibrutinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 181 participants |
| Start Date | 2014-07-07 |
| Est. Completion | 2019-11-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02165397
The ClinicalTrials.gov registry entry for NCT02165397 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 181 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pharmacyclics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02165397 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02165397 about?
NCT02165397 is a clinical study titled "Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia". The purpose of this study is to evaluate the safety and efficacy of ibrutinib in combination with rituximab in participants with Waldenström's macroglobulinemia (WM).
What is the current status of trial NCT02165397?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 181 participants. The study started on 2014-07-07. Estimated completion is 2019-11-07.
What interventions are being tested in trial NCT02165397?
The interventions under investigation include: Placebo (DRUG), Rituximab (DRUG), Ibrutinib (DRUG).
Who is sponsoring clinical trial NCT02165397?
This trial is sponsored by Pharmacyclics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.